Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Surgery still the only measure to cure RCC

Surgery still the only measure to cure RCC

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

AVEO Pharmaceuticals to present preclinical data from translational research platform at AACR 2010

AVEO Pharmaceuticals to present preclinical data from translational research platform at AACR 2010

Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout

Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout

NICE leaves many patients with rarer forms of cancer without drugs

NICE leaves many patients with rarer forms of cancer without drugs

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

ArQule reports net loss of $36,136,000 for 2009

ArQule reports net loss of $36,136,000 for 2009

Sorafenib drug therapy can reduce the size of primary kidney tumors before surgery

Sorafenib drug therapy can reduce the size of primary kidney tumors before surgery

Health Canada approves Novartis' Afinitor to treat patients with mRCC

Health Canada approves Novartis' Afinitor to treat patients with mRCC

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

PDGFR's role in new blood vessel formation may explain cardiovascular side effects

PDGFR's role in new blood vessel formation may explain cardiovascular side effects

Phase 2 clinical study of STA-9090 in NSCLC initiated

Phase 2 clinical study of STA-9090 in NSCLC initiated

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

New biomarkers can predict patients' response to certain drugs

New biomarkers can predict patients' response to certain drugs